BRPI1014887A8 - composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal - Google Patents

composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal

Info

Publication number
BRPI1014887A8
BRPI1014887A8 BRPI1014887A BRPI1014887A BRPI1014887A8 BR PI1014887 A8 BRPI1014887 A8 BR PI1014887A8 BR PI1014887 A BRPI1014887 A BR PI1014887A BR PI1014887 A BRPI1014887 A BR PI1014887A BR PI1014887 A8 BRPI1014887 A8 BR PI1014887A8
Authority
BR
Brazil
Prior art keywords
buccal
transmucosal
pharmaceutical composition
nasal dosage
sublingual
Prior art date
Application number
BRPI1014887A
Other languages
English (en)
Inventor
John Roos Calvin
Original Assignee
Londonpharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2009/050415 external-priority patent/WO2010122275A1/en
Priority claimed from GB0906971.7A external-priority patent/GB2469791B/en
Application filed by Londonpharma Ltd filed Critical Londonpharma Ltd
Publication of BRPI1014887A2 publication Critical patent/BRPI1014887A2/pt
Publication of BRPI1014887A8 publication Critical patent/BRPI1014887A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"composição farmacêutica para uso no tratamento de neoplasias e uso de um composto proven- do di-hidroartemesinina via dosagem sublingual, trans- mucosal, bucal ou nasal". a presente invenção refere-se a composições farmacêuticas para o tratamento de doenças neoplásicas, infestações por chistossoma e doença de lyme, que inclui compostos capazes de prover dihidroartemesin!na e triglicerídeos de cadeia média formulados para entregua transmucosal sublingual, bucal ou nasal, especialmente por um spray. também são providos dispositivos de aplicação contendo as composições.
BRPI1014887A 2009-04-23 2010-04-23 composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal BRPI1014887A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2009/050415 WO2010122275A1 (en) 2009-04-23 2009-04-23 Pharmaceutical preparation
GB0906971.7A GB2469791B (en) 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease
PCT/GB2010/050672 WO2010122356A1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin

Publications (2)

Publication Number Publication Date
BRPI1014887A2 BRPI1014887A2 (pt) 2016-04-19
BRPI1014887A8 true BRPI1014887A8 (pt) 2019-02-12

Family

ID=42244197

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014887A BRPI1014887A8 (pt) 2009-04-23 2010-04-23 composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal

Country Status (24)

Country Link
US (4) US20120157518A1 (pt)
EP (1) EP2424523B1 (pt)
JP (1) JP5795760B2 (pt)
CN (1) CN102395362B (pt)
AU (1) AU2010240654C1 (pt)
BR (1) BRPI1014887A8 (pt)
CA (1) CA2756925A1 (pt)
DK (1) DK2424523T3 (pt)
ES (1) ES2390046T3 (pt)
HK (1) HK1164140A1 (pt)
HR (1) HRP20120711T1 (pt)
IL (1) IL215453A (pt)
ME (1) ME02008B (pt)
MX (1) MX2011010961A (pt)
MY (1) MY155646A (pt)
NZ (1) NZ595469A (pt)
PL (1) PL2424523T3 (pt)
PT (1) PT2424523E (pt)
RS (1) RS52430B (pt)
RU (1) RU2501550C2 (pt)
SG (1) SG175162A1 (pt)
SI (1) SI2424523T1 (pt)
WO (1) WO2010122356A1 (pt)
ZA (1) ZA201107088B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
MX2011010835A (es) * 2009-04-23 2012-05-08 Londonpharma Ltd Composicion farmaceutica sublingual que comprende un aceite neutral.
JP6513576B2 (ja) * 2013-01-14 2019-05-15 ヘルス クリニックス リミテッド 抗がん剤および使用
WO2016083827A1 (en) 2014-11-27 2016-06-02 Cipla Limited Pharmaceutical composition comprising an artemisinin derivative for nasal or pulmonary delivery
JP2020033304A (ja) * 2018-08-30 2020-03-05 医療法人ふじいやさか 薬剤又はサプリメント、組成物、及び水素供給器の使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
CH692321A5 (de) * 1997-11-03 2002-05-15 Mepha Ag Pharmazeutisch wirksame Zusammensetzung, welche eine gegen Malariaparasiten wirksame Substanz enthält.
PL345503A1 (en) * 1998-07-14 2001-12-17 Bayer Ag Antiparasitic artemisinin derivatives (endoperoxides)
US20040092583A1 (en) * 2001-01-02 2004-05-13 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions
CA2487882A1 (en) * 2002-05-31 2003-12-11 University Of Mississippi Transmucosal delivery of cannabinoids
US20040058981A1 (en) * 2002-06-06 2004-03-25 University Of Washington Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
WO2004075921A1 (en) * 2003-02-26 2004-09-10 Vrije Universiteit Brussel Inclusion complex of artemisinin or derivates thereof with cyclodextrins
US20060084675A1 (en) * 2004-10-18 2006-04-20 Thomas Efferth Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor
US20060233895A1 (en) * 2005-04-15 2006-10-19 Brown Paul R Herbal remedy for treating Lyme disease
ATE544444T1 (de) * 2005-10-11 2012-02-15 Yissum Res Dev Co Zusammensetzungen für die nasale abgabe
CN100418524C (zh) * 2005-10-26 2008-09-17 重庆医药工业研究院有限责任公司 一种稳定的青蒿素及青蒿素衍生物的药物组合物

Also Published As

Publication number Publication date
JP5795760B2 (ja) 2015-10-14
SG175162A1 (en) 2011-11-28
AU2010240654B2 (en) 2014-05-08
PT2424523E (pt) 2012-10-03
HK1164140A1 (en) 2012-09-21
PL2424523T3 (pl) 2012-11-30
JP2012524772A (ja) 2012-10-18
DK2424523T3 (da) 2012-09-24
EP2424523B1 (en) 2012-06-27
US20160022629A1 (en) 2016-01-28
MY155646A (en) 2015-11-13
ME02008B (me) 2013-02-28
CA2756925A1 (en) 2010-10-28
IL215453A0 (en) 2011-12-29
AU2010240654C1 (en) 2014-08-14
AU2010240654A1 (en) 2011-10-20
ZA201107088B (en) 2012-12-27
US20190142737A1 (en) 2019-05-16
NZ595469A (en) 2013-10-25
CN102395362A (zh) 2012-03-28
US20120157518A1 (en) 2012-06-21
HRP20120711T1 (hr) 2012-10-31
RU2501550C2 (ru) 2013-12-20
US20170368023A1 (en) 2017-12-28
EP2424523A1 (en) 2012-03-07
SI2424523T1 (sl) 2012-11-30
ES2390046T3 (es) 2012-11-06
WO2010122356A1 (en) 2010-10-28
RU2011139637A (ru) 2013-05-27
MX2011010961A (es) 2012-04-20
CN102395362B (zh) 2014-07-02
BRPI1014887A2 (pt) 2016-04-19
IL215453A (en) 2014-11-30
RS52430B (en) 2013-02-28

Similar Documents

Publication Publication Date Title
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
BRPI1006115A8 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
HN2011001256A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratmiento o prevencion de diabetes
CR20180339A (es) INHIBIDORES DE PIRAZOLIL QUINAZOLINA CINASA (Divisional 2012-0576)
CR20110270A (es) Piriloxi-indoles Inhibidores del VEGF-R2 y Uso de los Mismos para el Tratamiento de Enfermedades
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
CR10479A (es) Modulares bencimidazolicos de vr1
EA200801997A1 (ru) Новые соединения
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
BRPI0817833A8 (pt) Composição farmacêutica antimalárica, dispositivo de medicamento de liberação, kits e usos de arteméter, arte-éter ou referida composição
TW200745122A (en) New compounds I
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
BRPI1014887A8 (pt) composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto
UA107455C2 (uk) Похідні індолу як протиракові агенти
TW200745133A (en) New compounds II
UY29161A1 (es) Nuevos heterociclos
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]